Jennifer Mataraza

2.0k total citations
24 papers, 1.4k citations indexed

About

Jennifer Mataraza is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Jennifer Mataraza has authored 24 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 10 papers in Immunology and 8 papers in Molecular Biology. Recurrent topics in Jennifer Mataraza's work include Cancer Immunotherapy and Biomarkers (9 papers), CAR-T cell therapy research (8 papers) and Immune cells in cancer (4 papers). Jennifer Mataraza is often cited by papers focused on Cancer Immunotherapy and Biomarkers (9 papers), CAR-T cell therapy research (8 papers) and Immune cells in cancer (4 papers). Jennifer Mataraza collaborates with scholars based in United States, Switzerland and Spain. Jennifer Mataraza's co-authors include Thomas C. Chiles, David B. Sacks, David Carnahan, K. Kempa, Zhifeng Ren, Zheng‐Hong Qin, Zhongping Huang, Dong Cai, Jianyu Huang and Mary F. Roberts and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Jennifer Mataraza

24 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jennifer Mataraza United States 14 662 348 330 265 205 24 1.4k
Ricardo Brandwijk Netherlands 15 779 1.2× 478 1.4× 214 0.6× 180 0.7× 252 1.2× 19 1.4k
Guillaume Normand United States 15 604 0.9× 340 1.0× 232 0.7× 171 0.6× 95 0.5× 32 1.5k
Min Qian China 18 620 0.9× 181 0.5× 179 0.5× 151 0.6× 82 0.4× 35 1.1k
Fabio Cerignoli United States 22 1.1k 1.7× 144 0.4× 293 0.9× 199 0.8× 141 0.7× 30 1.6k
Taranjit S. Gujral United States 22 1.0k 1.6× 130 0.4× 462 1.4× 418 1.6× 119 0.6× 58 1.9k
Mira Barda‐Saad Israel 25 799 1.2× 1.1k 3.3× 487 1.5× 181 0.7× 113 0.6× 55 2.2k
Maonan Wang China 14 663 1.0× 323 0.9× 483 1.5× 314 1.2× 151 0.7× 35 1.5k
Charles Y. Cho United States 20 1.8k 2.8× 126 0.4× 294 0.9× 276 1.0× 146 0.7× 27 2.8k
Sébastien Tosi Spain 13 702 1.1× 146 0.4× 675 2.0× 258 1.0× 104 0.5× 26 1.6k
C. Boyer France 20 533 0.8× 277 0.8× 375 1.1× 92 0.3× 108 0.5× 45 1.6k

Countries citing papers authored by Jennifer Mataraza

Since Specialization
Citations

This map shows the geographic impact of Jennifer Mataraza's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jennifer Mataraza with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jennifer Mataraza more than expected).

Fields of papers citing papers by Jennifer Mataraza

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jennifer Mataraza. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jennifer Mataraza. The network helps show where Jennifer Mataraza may publish in the future.

Co-authorship network of co-authors of Jennifer Mataraza

This figure shows the co-authorship network connecting the top 25 collaborators of Jennifer Mataraza. A scholar is included among the top collaborators of Jennifer Mataraza based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jennifer Mataraza. Jennifer Mataraza is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Ikegawa, Shuntaro, Adam S. Sperling, Michela Ansuinelli, et al.. (2023). T-Charge™ Manufacturing of the Anti-BCMA CAR-T, Durcabtagene Autoleucel (PHE885), Promotes Expansion and Persistence of CAR-T Cells with High TCR Repertoire Diversity. Blood. 142(Supplement 1). 3469–3469. 5 indexed citations
3.
Wang, Hui Qin, Iain J. Mulford, Fiona A. Sharp, et al.. (2021). Inhibition of MDM2 Promotes Antitumor Responses in p53 Wild-Type Cancer Cells through Their Interaction with the Immune and Stromal Microenvironment. Cancer Research. 81(11). 3079–3091. 43 indexed citations
4.
5.
Piha‐Paul, Sarina A., Ravit Geva, Tira J. Tan, et al.. (2021). First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas. Journal for ImmunoTherapy of Cancer. 9(8). e002863–e002863. 35 indexed citations
6.
Wu, Jincheng, Marta Gil-Martín, Aung Naing, et al.. (2020). Abstract CT172: Pharmacodynamic and gene expression profiling of patients treated with BLZ945 + spartalizumab demonstrates on-target peripheral and tumor immune microenvironment modulation. Cancer Research. 80(16_Supplement). CT172–CT172. 2 indexed citations
7.
Naing, Aung, Justin F. Gainor, Hans Gelderblom, et al.. (2020). A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti–PD-1 antibody, in patients with advanced solid tumors. Journal for ImmunoTherapy of Cancer. 8(1). e000530–e000530. 63 indexed citations
8.
Wang, Hui Qin, Jinsheng Liang, Iain J. Mulford, et al.. (2018). Abstract 5560: PD-1/PD-L1 blockade enhances MDM2 inhibitor activity in p53 wild-type cancers. Cancer Research. 78(13_Supplement). 5560–5560. 3 indexed citations
9.
Calvo, Aitana, Heikki Joensuu, Martin Sebastian, et al.. (2018). Phase Ib/II study of lacnotuzumab (MCS110) combined with spartalizumab (PDR001) in patients (pts) with advanced tumors.. Journal of Clinical Oncology. 36(15_suppl). 3014–3014. 36 indexed citations
10.
Taylor, Matthew H., Valentina Boni, Paal Brunsvig, et al.. (2018). Phase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with advanced melanoma or non-small cell lung cancer. Annals of Oncology. 29. viii413–viii413. 11 indexed citations
11.
Mataraza, Jennifer & Philip J. Gotwals. (2016). Recent advances in immuno‐oncology and its application to urological cancers. British Journal of Urology. 118(4). 506–514. 10 indexed citations
12.
Mataraza, Jennifer, et al.. (2007). Multiple proteins mediate IQGAP1-stimulated cell migration. Cellular Signalling. 19(9). 1857–1865. 31 indexed citations
13.
Jadeski, Lorraine, Jennifer Mataraza, Ha‐Won Jeong, Zhigang Li, & David B. Sacks. (2007). IQGAP1 Stimulates Proliferation and Enhances Tumorigenesis of Human Breast Epithelial Cells. Journal of Biological Chemistry. 283(2). 1008–1017. 116 indexed citations
14.
Doughty, Cheryl A., Dean J. Wagner, Fay J. Dufort, et al.. (2006). Antigen receptor–mediated changes in glucose metabolism in B lymphocytes: role of phosphatidylinositol 3-kinase signaling in the glycolytic control of growth. Blood. 107(11). 4458–4465. 289 indexed citations
15.
Mataraza, Jennifer, et al.. (2006). Disruption of Cyclin D3 Blocks Proliferation of Normal B-1a Cells, but Loss of Cyclin D3 Is Compensated by Cyclin D2 in Cyclin D3-Deficient Mice. The Journal of Immunology. 177(2). 787–795. 12 indexed citations
16.
Cai, Dong, Jennifer Mataraza, Zheng‐Hong Qin, et al.. (2005). Highly efficient molecular delivery into mammalian cells using carbon nanotube spearing. Nature Methods. 2(6). 449–454. 384 indexed citations
17.
Mataraza, Jennifer, et al.. (2004). B Cell Receptor-induced cAMP-response Element-binding Protein Activation in B Lymphocytes Requires Novel Protein Kinase Cδ. Journal of Biological Chemistry. 279(29). 30123–30132. 37 indexed citations
18.
Cifuentes-Pagano, Eugenia, Jennifer Mataraza, Barbara A. Yoshida, et al.. (2003). Physical and functional interaction of androgen receptor with calmodulin in prostate cancer cells. Proceedings of the National Academy of Sciences. 101(2). 464–469. 38 indexed citations
19.
Mataraza, Jennifer, Michael W. Briggs, Zhigang Li, et al.. (2003). IQGAP1 Promotes Cell Motility and Invasion. Journal of Biological Chemistry. 278(42). 41237–41245. 179 indexed citations
20.
Mataraza, Jennifer, Michael W. Briggs, Zhigang Li, Ronald Frank, & David B. Sacks. (2003). Identification and characterization of the Cdc42-binding site of IQGAP1. Biochemical and Biophysical Research Communications. 305(2). 315–321. 43 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ricardo Brandwijk Breakdown of academic impact, for papers by Guillaume Normand Breakdown of academic impact, for papers by Min Qian Breakdown of academic impact, for papers by Fabio Cerignoli Breakdown of academic impact, for papers by Taranjit S. Gujral Breakdown of academic impact, for papers by Mira Barda‐Saad Breakdown of academic impact, for papers by Maonan Wang Breakdown of academic impact, for papers by Charles Y. Cho Breakdown of academic impact, for papers by Sébastien Tosi Breakdown of academic impact, for papers by C. Boyer
Rankless by CCL
2026